DavidEricGerberMD

Oncology • Dallas, TX

Thoracic Cancer

Professor of Internal Medicine (Hematology-Oncology) and Population & Data Sciences

Join to view full profile

Dr. Gerber is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gerber's full profile

Already have an account?

Office
5323 Harry Hines Boulevard
Dallas, TX 75390
Phone+1 214-645-4673

Fax+1 214-645-2615
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2000 - 2004
Weill Cornell MedicineClass of 2000

Certifications & Licensure

TX State Medical License 2002 - 2024
MD State Medical License 2004 - 2008
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies Start of enrollment: 2005 Jun 01
Completed
Phase 1
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2009 Sep 01
Completed
Phase 1
Clinical Trial of ARQ 761 in Advanced Solid Tumors Start of enrollment: 2011 Dec 29
Completed
Phase 1
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer Start of enrollment: 2013 Jan 10
Terminated
Phase 3
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Start of enrollment: 2013 Sep 01
Completed
Phase 2
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Completed
Phase 3
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Completed
Phase 2
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas Start of enrollment: 2019 Sep 11
Recruiting
Phase 2
Roles: Sponsor-Investigator, Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable Populations.
Sheena Bhalla, Vijaya Natchimuthu, Jessica L Lee, Urooj Wahid, Hong Zhu, Noel O Santini, Travis Browning, Heidi A Hamann, David H Johnson, Hsienchang Chiu, Simon J Cra...> ;Journal of the National Comprehensive Cancer Network. 2024 Mar 15
Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important Entity.
Mitchell S von Itzstein, David E Gerber> ;Clinical Chemistry. 2024 Apr 3
The Joint Problem of Rheumatoid Arthritis and Lung Cancer.
Bermas, B., Gerber, D.> ;Journal of Thoracic Oncology. 2024 Feb 1
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.
Wang, Y., Sun, Z., Brahmer, J., Schiller, J., Gerber, D., Ramalingam, S., Bhalla, S., Borghaei, H.> ;The Oncologist. 2024 Jan 11
Emerging Strategies in Lung Cancer Screening: Blood and Beyond.
Yi, S., Bhalla, S., Gerber, D.> ;Clinical Chemistry. 2024 Jan 4
A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Ea...
Wang, H., Shaverdashvili, K., Reyes, V., Mehta, D., Marsh, C., Waas, J., VanderWeele, R., Peracha, S., Liang, H., Socinski, M., Gerber, D., Dowell, J., Villaruz, L.> ;Eclinicalmedicine. 2023 Dec 1
Contemporary Trends in Reviewing Test Results Through the Electronic Patient Portal Among Patients With Cancer.
Sheena Bhalla, Tanushree Prasad, Donglu Xie, David E Gerber> ;JAMA Oncology. 2024 Jan 1
Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer.
Ananda M Rodilla, Rajesh M Valanparambil, Philip C Mack, Chih-Yuan Hsu, Jazz Cagan, Sooyun C Tavolacci, Juan Manuel Carreño, Rachel Brody, Amy Moore, Jennifer C King, ...> ;Cancer Cell. 2023 Nov 13
Initial Steps in Creating a Patient-Centric Addendum to Clinical Trial Informed Consent Forms.
Bellinda L King-Kallimanis, Andrea Ferris, Lisa Dropkin, Mariel Molina, Lydia Redway, David E Gerber, Tracey L Grant, Upal Basu Roy> ;JTO Clinical and Research Reports. 2023 Oct 1
9 citations
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on o...
Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo, Jaromir Roubec, Lubos Petruzelka, Libor Havel, Sujith Kalmadi, Jeffrey Ward, Zor...> ;The Lancet. Oncology. 2023 Sep 1
Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors.
Mundra, V., Yang, Y., von Itzstein, M., Fattah, F., Gonugunta, A., Hannan, R., Pop, L., Zhang, Y., Wang, Y., Sheffield, T., Xie, Y., Dowell, J., Homsi, J., Rashdan, S....> ;Translational Oncology. 2023 Aug 1
T-cell tolerant fraction as a predictor of immune-related adverse events.
Jared Ostmeyer, Jason Y Park, Mitchell S von Itzstein, David Hsiehchen, Farjana Fattah, Mary Gwin, Rodrigo Catalan, Shaheen Khan, Prithvi Raj, Edward K Wakeland, Yang ...> ;Journal for Immunotherapy of Cancer. 2023 Aug 1
1 citations
Taking It to the States: Adapting Information Blocking Legislation to Oncology.
David E Gerber> ;Journal of Clinical Oncology. 2023 Sep 20
4 citations
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer.
Sheena Bhalla, Farjana J Fattah, Chul Ahn, Jessica Williams, Alyssa Macchiaroli, Jonathan Padro, Meredith Pogue, Jonathan E Dowell, William C Putnam, Nigel McCracken, ...> ;Lung Cancer. 2023 Aug 1
1 citations
An Updated Report on the Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer in the Surveillance, Epidemiology, and End Results Program.
Caitlin C Murphy, Guillermo A Tortolero, David E Gerber, Sandi L Pruitt> ;JAMA Oncology. 2023 Aug 1
2 citations
Approaches to Continuing COVID-19-Related Clinical Research Practices After the Pandemic-Must Cinderella Leave the Ball?
David E Gerber, Elizabeth K S Barksdale> ;JAMA Oncology. 2023 Aug 1
Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies.
Alexis C Boulter, Barry J Maurer, Meredith Pogue, Min H Kang, Hwangeui Cho, Amanda Knight, C Patrick Reynolds, Donald Quick, Sanjay Awasthi, David E Gerber> ;Cancer Chemotherapy and Pharmacology. 2023 Aug 1
8 citations
AXL Inhibitors: Status of Clinical Development.
Sheena Bhalla, David E Gerber> ;Current Oncology Reports. 2023 May 1
3 citations
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembroli...
Charles M Rudin, Hardev S Pandha, Matthew Zibelman, Wallace L Akerley, Kevin J Harrington, Daphne Day, Andrew G Hill, Steven J O'Day, Timothy D Clay, Gavin M Wright, R...> ;Journal for Immunotherapy of Cancer. 2023 Jan 1
3 citations
Survival of cancer survivors with a new pancreatic cancer diagnosis.
Sandi L Pruitt, Anna Tavakkoli, Hong Zhu, Daniel F Heitjan, Amit G Singal, Ethan A Halm, Muhammad Shaalan Beg, Bhumika Maddineni, Ankit J Kansagra, Caitlin C Murphy, G...> ;Cancer Medicine. 2023 Jan 1
Better Late Than Never: Fully Incorporating Oncology Advanced Practice Providers Into Cancer Clinical Trials.
Christa Braun-Inglis, Erin L Williams, Alyssa Macchiaroli, Andrea Denicoff, Gerber, D.> ;JCO Oncology Practice. 2022 Nov 1
14 citations
Oncologic emergencies and urgencies: A comprehensive review.
Bonnie E Gould Rothberg, Tammie E Quest, Sai-Ching J Yeung, Lorraine C Pelosof, David E Gerber, Justin A Seltzer, Jason J Bischof, Charles R Thomas Jr, Nausheen Akhter...> ;CA. 2022 Nov 1
Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study.
Antigona Ulndreaj, Davor Brinc, Mehmet Altan, Oscar D Pons-Belda, Amaia Fernandez-Uriarte, Hong Mu-Mosley, Farjana Fattah, Mitchell S von Itzstein, Antoninus Soosaipil...> ;Clinical Chemistry and Laboratory Medicine. 2023 Jan 27
1 citations
Enhancing access to and diversity in cancer clinical trials through a financial reimbursement program: Protocol to evaluate a novel program.
Jasmin A Tiro, Lorna H McNeill, Erin L Williams, Hong Zhu, Simon J Craddock Lee, Patrick J Leavey, Navid Sadeghi, Kandice A Kapinos, Dana L Dornsife, Vivian Nguyen, E ...> ;Contemporary Clinical Trials. 2022 Oct 1
Placing a Cancer Diagnosis in Clinical Context: Applying Functional Trajectories to Advanced NSCLC.
Heidi A Hamann, David E Gerber> ;JTO Clinical and Research Reports. 2022 Sep 1
Join now to see all

Journal Articles

Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases
David E Gerber, Jonathan E Dowell, Clinical Lung Cancer

Lectures

Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical TrialsClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Underlying host immune dysregulation in cancer patients developing immune-related adverse events.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Authored Content

Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published CasesNovember 2018

Press Mentions

Weight-Based Immunotherapy Dosing May Benefit Patients with Cancer and High BMIJune 22nd, 2021
UT Southwestern: Criteria for Clinical Trials Might Be Too StrictDecember 10th, 2019
Strange Signs: Cancer-Related Paraneoplastic SyndromesNovember 15th, 2019
Join now to see all